Patents Assigned to Inserm
  • Methods for selecting binders by phage display and masked selection
    Patent number: 9605257
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: March 28, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Methods for expressing a polynucleotide of interest in the retina of a subject
    Patent number: 9597415
    Abstract: Provided herein are methods for expressing a polynucleotide of interest in the retina of a subject. In particular, a method for expressing a polynucleotide of interest in the retina of a subject comprising the step consisting of injecting into the vitreous an amount of a vector containing the polynucleotide of interest in combination with an amount of an inhibitor of Dp71 expression is provided.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: March 21, 2017
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Deniz Dalkara, Alvaro Rendon Fuentes, Jose Alain Sahel, Ophelie Vacca
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Detection of SHED CD31, Diagnosis of Atherothrombosis and Autoimmune Disorders, and Methods for Analyzing Signaling Pathways
    Publication number: 20170074891
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex.
    Type: Application
    Filed: December 16, 2014
    Publication date: March 16, 2017
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • POOLED NK CELLS FROM OMBILICAL CORD BLOOD AND THEIR USES FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIOUS DISEASE
    Publication number: 20170073637
    Abstract: The invention relates to the field of cell therapy, particularly NK cell mediated therapy. The present invention relates to a method of producing an ex vivo population of cells, preferably NK cells, from at least two umbilical cord blood units (UCB units), or fraction thereof containing said cells, by pooling said at least two UCB units to produce said population of cells. The present invention relates to the use of said cells, preferably NK cells, obtainable or obtained by the process according to the invention, as a composition for therapeutic use, preferably for the treatment of cancer and chronic infectious disease.
    Type: Application
    Filed: March 9, 2015
    Publication date: March 16, 2017
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE RECHERCHE MEDICALE (INSERM)
    Inventors: Patrick HENNO, Martin VILLALBA GONZALEZ
  • Modified apelin polypeptides
    Patent number: 9593153
    Abstract: The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, UNIVERSITE DE BORDEAUX
    Inventors: Geraldine Siegfried, Abdel-Majid Khatib
  • Method for the treatment of cardiovascular fibrosis
    Patent number: 9594083
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Lorraine, Cantre Hospitalier et Universitaire de Nancy (CHU), Universite Paris Diderot-Paris 7, Universite Paris Descartes
    Inventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
  • Compounds for the treatment of autism in a baby child
    Patent number: 9592214
    Abstract: The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons for use in the treatment of autism in a baby or a fetus in need thereof.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 14, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, CHU DE BREST
    Inventors: Yehezkel Ben-Ari, Diana Carolina Ferrari, Romain Nardou, Eric LeMonnier
  • 28 kDa GST proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a Th1 and/or Th17 response
    Patent number: 9593313
    Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 14, 2017
    Assignees: UNIVERSITE DU DROIT ET DE LA SANTE DE LILLE 2, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventors: Monique Capron, Mohamed El Nady, Jean-Frederic Colombel, Gilles Riveau
  • Natural killer p30 (NKp30) dysfunction and the biological applications thereof
    Patent number: 9593376
    Abstract: The present invention relates to a method of assessing a favorable or, on the contrary, an unfavorable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of cancer in the subject.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: March 14, 2017
    Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Laurence Zitvogel, Nicolas Delahaye
  • METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME
    Publication number: 20170067105
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU
  • Recombinant monovalent antibodies
    Patent number: 9587023
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Microparticles supporting cells and active substances
    Patent number: 9579287
    Abstract: A method of repairing tissue includes implanting into a patient a therapeutically effective amount of a pharmaceutical composition including microparticles including a biodegradable, biocompatible material having cells of interest or fragments thereof adhered to at least a portion of a surface; and at least one substance active on the cells or their environment upon implantation of the microparticles in a patient associated with the material wherein the substances is released in a controlled or extended manner.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: February 28, 2017
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Claudia Montero-Menei, Philippe Menei, Jean-Pierre Benoit, Valérie Tatard, Marie-Claire Venier
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VASO-OCCLUSIVE CRISIS
    Publication number: 20170049862
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating vaso-occlusive crises. In particular, the present invention relates to a method of treating a vaso-occlusive crisis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of agent capable of degrading, destabilizing or depleting the blood-borne extracellular DNA from the blood of the subject.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 23, 2017
    Applicants: Inserm (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Olivier BLANC-BRUDE, Sylvain LEJEUNE
  • Melanoma antigen peptide and uses thereof
    Patent number: 9573975
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: February 21, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, François Lang, Mathilde Bobinet, Anne Rogel
  • Methods for treating cone dystrophy with neuronal viability factor, RDCVF2
    Patent number: 9575075
    Abstract: The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 21, 2017
    Assignees: INSERM (Institut National de la Sante et Recherche Medicale), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
  • Method for use in the treatment of aneurysm
    Patent number: 9573997
    Abstract: The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 21, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
    Inventors: Ziad Mallat, Soraya Taleb, Alain Tedgui
  • Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids
    Patent number: 9572776
    Abstract: The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: February 21, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Virginie Escriou, Pascal Bigey, Daniel Scherman
  • METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
    Publication number: 20170044533
    Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 16, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CNRS (Centre National de la Recherche Scientifique), GENETHON, UNIVERSITE PARIS DESCARTES, ENSCP - Chimie ParisTech - Ecole Nationale Superieure de Chimie de Paris, Universite d'Evry-Val-d'Essonne, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Jean-Michel ROZET, Antoine KICHLER, Isabelle PERRAULT, Josseline KAPLAN, Xavier GERARD, Daniel SCHERMAN, M. Arnold MUNNICH
  • POLYPEPTIDES AND USES THEREOF FOR REDUCING CD95-MEDIATED CELL MOTILITY
    Publication number: 20170044234
    Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Applicant: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Patrick LEGEMBRE, Pierre VACHER, Doriane SANSEAU, Aubin PENNA, Robin FLYNN